Fusion protein technologies for biopharmaceuticals : applications and challenges /
The state of the art in biopharmaceutical FUSION PROTEIN DESIGN Fusion proteins belong to the most lucrative biotech drugs-with Enbrel® being one of the best-selling biologics worldwide. Enbrel® represents a milestone of modern therapies just as Humulin®, the first therapeutic recombinant protein fo...
| Other Authors: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Hoboken, New Jersey :
John Wiley & Sons,
[2013]
|
| Subjects: | |
| Online Access: | Full Text via HEAL-Link |
Table of Contents:
- pt. 1. Introduction
- pt. 2. The triple t paradigm : time, toxin, targeting
- pt. 3. Beyond the triple t-paradigm.